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90S Abstracts June Supplement 2014cardiothoracic and general vascular procedures, such as aortic
artery grafting or aneurysm, which necessitate long abdom-
inal incisions. Additionally, it could be performed if a major
vessel is injured during any of the common laparoscopic pro-
cedures before transforming the technique to an open one.
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Factors Affecting the Response of the Vascular
Endothelium to the Microsuturing Trauma
Rania Bakry. Clinical Pathology, Assiut University, Assiut,
Egypt
Objectives: Many researchers have investigated micro-
vascular anastomoses by scanning electron microscope
(SEM); however, there are neither reports on classifying
these anastomotic types according to the SEM results nor
about studying the factors that affect these results.
Methods: Sixty rat femoral arteries were anastomosed
using four different techniques: simple interrupted, contin-
uous, sleeve, and autogenous arterial cuff. The anastomotic
sites of each group and other two intact femoral arteries
were examined by SEM.
Results: Intimal disruption and rebuilding of the
blood vessel endothelium after microvascular anastomo-
ses depend upon anastomotic time; suture placement,
either intraluminal or extraluminal; and mechanical fac-
tors. Accordingly, the simple interrupted suture tech-
nique has the highest degree of intimal disruption and
the lowest degree of regeneration, the continuous and
cuff anastomoses have better rebuilding with partial
neoendothelial coverage of the cut ends, whereas the
sleeve anastomosis has the best regeneration with com-
plete coverage of the cut ends by the new endothelial
cells.
Conclusions: This study shows that intimal disrup-
tion and rebuilding of blood vessel endothelium after
microvascular anastomoses depend upon three factors:
anastomotic time, suture placement, and mechanical
factors.
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A Propensity Adjusted Analysis of Open and
Endovascular Thoracic Aortic Repair for Chronic
Type B Dissection: A 20-Year Evaluation
Guido H. van Bogerijen, Himanshu J. Patel, David M.
Williams, Bo Yang, Narasimham L. Dasika, Jonathan L.
Eliason, G. M. Deeb. University of Michigan Samuel
and Jean Frankel Cardiovascular Center, Ann Arbor,
Mich
Objectives: Optimal treatment of chronic type B
aortic dissection (CBAD), whether open (DTAR) or endo-
vascular (TEVAR), is controversial, suggesting a compara-
tive analysis is warranted.
Methods: Of 1049 patients (1993-2013) undergo-
ing descending aortic repair, 122 required interventionfor CBAD 29.2 6 34.9 months after the initial acute
event and formed the study cohort (mean age, 59.7
years). Those with a degenerated residual type A dissec-
tion were excluded. Eighty-eight had extent IIIB
CBAD, and 11 had intramural hematoma. Indication
for surgery included aneurysmal degeneration (105),
rupture (8), acute on chronic dissection (8), and exten-
sion (1). Open strategy included descending (71) and
thoracoabdominal repair (19), with hypothermic arrest
used in 66. TEVAR was performed with (two) or
without (30) visceral debranching. A treatment strategy
propensity score incorporating time since initial acute
event, CBAD extent, year of intervention, age, and
selected comorbidities was constructed for multivariable
analysis.
Results: Early outcome included: 30-day mortality,
4% (n ¼ 5); permanent paraplegia, 3% (n ¼ 4); stroke,
2% (n ¼ 2); dialysis, 7% (n ¼ 8); and tracheostomy, 3%
(n ¼ 4). Visceral aorta intervention (OR, 3.5; P ¼ .03)
and mean aortic diameter (OR, 1.1; P ¼ .001), but not
treatment type (P ¼ .6) independently predicted an early
composite outcome consisting of these variables. Ten-
year survival was 56.2%. Baseline creatinine (HR, 1.7; P
< .001) and peripheral vascular disease (HR, 2.4; P ¼
.03), but not treatment type (P ¼ .2) predicted late mortal-
ity. Ten-year freedom from aortic rupture/need for rein-
tervention was 76.7%. Treatment efﬁcacy was improved
after DTAR (3-year freedom, 96.2% vs TEVAR, 71.8%;
P ¼ .004), and this was conﬁrmed after Cox regression
(TEVAR HR, 3.2; P ¼ .04).
Conclusions: Intervention for chronic type B aortic
dissection can be performed with excellent results,
either by an open or endovascular approach. The higher
rate of treatment failure after TEVAR warrants modiﬁ-
cation of the current device design or endovascular
approach before broad application of this treatment
strategy.
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other remuneration (payment); G. H. van Bogerijen:
Nothing to disclose; D. M. Williams: W. L. Gore, consul-
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Beneﬁt of EndoAnchors in Endovascular Aneurysm
Repair: Analysis by Indication for Use
Jean-Paul de Vries1, Manish Mehta2, Kenneth Ouriel3,
William Jordan4. 1St Antonius Hospital, Nieuwegein,
The Netherlands; 2Institute for Vascular Health and
Disease, Albany, NY; 3Syntactx, New York, NY;
4University of Alabama-Birmingham, Birmingham, Ala
Objectives: EndoAnchors (EAs) have been used as
an adjunct to endovascular aneurysm repair (EVAR) in
patients with challenging aortic neck anatomy. The aim
of this study was to assess outcome by indication for
EA use.
Methods: A total of 319 patients were enrolled at 43
sites in ANCHOR, a prospective, multinational, real-world
study of EA implantation for ﬁrst-time EVAR (primary
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remote from an initial endovascular repair (revision arm,
n ¼ 77). The primary arm was subdivided into (1) prophy-
lactic EA use for hostile neck anatomy, (2) use for acute
type Ia endoleak after endograft deployment, and (3) use
after unsatisfactory distal endograft deployment. The revi-
sion arm was subdivided into those undergoing treatment
for (1) type Ia endoleak alone, (2) migration alone, and
(3) migration with endoleak. Procedural success was
deﬁned as successful EA implantation without type Ia
endoleak on completion angiography, and clinical success
was deﬁned as procedural success without type Ia endoleak,
migration, >5 mm sac enlargement, or secondary proce-
dures over follow-up.
Results: Outcome after EA use was satisfactory over
early follow-up averaging 9 6 3 months, with absence of
type Ia endoleaks in 290 patients (90.9%), procedural suc-
cess in 279 patients (87.5%), and clinical success in 265 pa-
tients (83.1%) (Table).
Conclusions: EAs appear to offer a useful adjunct to
EVAR for prophylaxis against aortic neck complications
when hostile anatomy is encountered, and therapeutically
when aortic neck complications develop. Deﬁnitive conclu-










No. (%) No. (%) No. (%)
Primary arm 242 19 (7.9) 217 (89.7) 208 (86.0)
Prophylactic 186 9 (4.8) 172 (92.5) 165 (88.7)
Acute endoleak 52 9 (17.3) 43 (82.7) 41 (78.8)
Distal deployment 4 1 (25.0) 2 (50.0) 2 (50.0)
Revision arm 77 10 (13.0) 62 (87.5) 57 (74.0)
Existing endoleak 45 9 (20.0) 35 (77.8) 32 (71.1)
Existing Migration 11 0 8 (72.2) 8 (72.7)
Endoleak and
migration
21 1 (4.8) 19 (90.5) 17 (81.0)Author Disclosures: J. de Vries: Aptus Endosystems,
research grants and Honorarium;W. Jordan: Aptus Endo-
systems, research grants and consulting fees or other remu-
neration (payment); M. Mehta: Aptus Endosystems,
research grants; K. Ouriel: Syntactx, employment (full or
part-time), and ownership or partnership, and Aptus Endo-
systems, consulting fees or other remuneration (payment).Table. ROC analyses of risk prediction models for disease prog
Risk of disease progression
Unadjusted HR (95% CI) Adjusted HR* (95%
PSV 1.01 (1.01-1.02) 1.01 (1.01-1.02
EDV 1.02 (1.01-1.03) 1.03 (1.01-1.04
ICA/CCA ratio 3.90 (2.19-5.25) 3.42 (2.16-5.41
PSV + ICA/CCA 2.60 (1.59-4.25) 2.63 (1.54-4.47
AUC, Area under the curve; CI, conﬁdence interval; HR, hazard ratio.
*Adjusted for age, smoking, and dual antiplatelet therapy.
**Model equation: Y ¼ exp(e4.84 + 0.005PSV e 0.97ratio e0.007Age + 0.56RR3.
Disease Progression in Patients with Moderate
Asymptomatic Carotid Artery Stenosis: Development
of a Risk Prediction Model
Caitlin W. Hicks1, Joseph K. Canner1, Isibor Arhuidese2,
Eric Schneider1, Umair Qazi2, Katherine Talbott2,
Christopher J. Abularrage1, Julie A. Freischlag1, Bruce
Perler1, Mahmoud B. Malas1. 1Johns Hopkins Hospital,
Baltimore, Md; 2Johns Hopkins Bayview Medical Center,
Baltimore, Md
Objectives: Previously, we described risk factors for
disease progression in moderate asymptomatic carotid ar-
tery stenosis (ASCS). The aim of the current study was
to develop a risk prediction model for disease progression
in this group.
Methods: All patients presenting with moderate
(50%-69%) ASCS as determined by carotid artery duplex
(January 2005-May 2012) were included. Cox propor-
tional hazard regression models accounting for measured
duplex velocities (peak systolic velocity [PSV]; end-dia-
stolic velocity [EDV]; internal carotid artery [ICA]/
common carotid artery [CCA] ratio) and previously
identiﬁed risk factors for progression (age, smoking,
dual antiplatelet therapy) were used to develop receiver
operating characteristic (ROC) curves for predicting dis-
ease progression.
Results: A total of 268 patients (52% male) were
analyzed (71 6 9 years, 2.6 6 1.7 years followup, 25% dis-
ease progression). Initial PSV, EDV, and ICA/CCA ratio
were all signiﬁcant predictors of progression (Table).
ROC curve analyses suggested that a prediction model
including PSV, ICA/CCA ratio, age, smoking, and dual
antiplatelet therapy had optimal prediction efﬁcacy (C-sta-
tistic, 0.76; Table).
Conclusions: We propose a ﬁve-variable risk predic-
tion model that can be used to predict disease progression
in patients with moderate ASCS with good sensitivity and
speciﬁcity that may be useful for identifying high-risk pa-
tients requiring closer follow-up.
AuthorDisclosures: C. J. Abularrage: Nothing to disclose;
I. Arhuidese: Nothing to disclose; J. K. Canner: Nothing to
disclose; J. A. Freischlag: Nothing to disclose;C.W.Hicks:
Nothing to disclose; M. B. Malas: Nothing to disclose; B.
Perler: Nothing to disclose; U. Qazi: Nothing to disclose;
E. Schneider: Nothing to disclose; K. Talbott: Nothing to
disclose.ression in moderate asymptomatic carotid artery stenosis
C-statistic
CI) Unadjusted AUC (95% CI) Adjusted AUC* (95% CI)
) 0.68 (0.61-0.76) 0.71 (0.63-0.79)
) 0.64 (0.56-0.72) 0.68 (0.60-0.76)
) 0.74 (0.68-0.81) 0.75 (0.68-0.76)
) 0.75 (0.68-0.82) 0.76 (0.69-0.83)
Smoking + 0.40Antiplatelet).
